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Mumps Virus–
associated
Hemophagocytic
Syndrome
To the Editor: Virus-associated
hemophagocytic syndrome (VAHS) is
a fulminant disorder associated with
systemic viral infection and is charac-
terized pathologically by the prolifer-
ation of hemophagocytic histiocytes
in the lymphoreticular tissues. Here
we report a case of mumps VAHS fol-
lowing parotitis and pancreatitis.
A 39-year-old, previously healthy
woman sought treatment for abdomi-
nal pain on June 14, 2002. On physical
examination, her bilateral parotid
glands were swollen, and her left
upper quadrant was tender. Laboratory
studies showed a leukocyte count of
4,640/mm3, a hemoglobin concentra-
tion of 13.9 g/dL, and a platelet count
of 19.1 × 104/mm3. The level of amy-
lase was elevated in her blood (1,613
IU/L; normal 50–160 IU/L) and urine
(12,940 IU/L; normal 200–1,100
IU/L). Her level of pancreatic
enzymes was also elevated: lipase
level was 194 IU/L (normal 7–60
IU/L) and phospholipase A2 level was
1,340 ng/dL (normal 130–400 ng/dL).
Parotitis and acute pancreatitis due to
a mumps virus infection were diag-
nosed. After supportive therapy,  the
laboratory abnormalities improved.
On July 1, the patient’s tempera-
ture suddenly rose to 39°C. At that
time, pancytopenia was evident, with
a leukocyte count of 2,350/mm3, a
hemoglobin concentration of 10.9
g/dL, and a platelet count of 9.1 ×
104/mm3. Laboratory studies showed
an elevation of lactic dehydrogenase
(1,403 IU/L; normal 180–460 IU/L),
ferritin (12,727.0 ng/mL; normal
4.0–64.2 ng/mL), and soluble inter-
leukin-2 receptors (1,660 U/mL; nor-
mal 145–519 U/mL). Hypercyto-
kinemia was also shown, with an
interleukin-6 of 12.7 pg/mL (normal
<3.1 pg/mL). Her bone marrow was
normocellular, and an increased num-
ber of histiocytes with hemophagocy-
tosis was found. Extensive cultures
and serologic studies for microbial
and viral infections were all negative,
whereas tests for immunoglobulin G
and immunoglobulin M antibodies
against the mumps virus were
both positive. Mumps VAHS was
diagnosed. Treatment with corticos-
teroids led to a complete remission of
symptoms. 
VAHS was initially reported by
Risdall et al. in 1979 (1). Although the
precise pathogenesis of VAHS
remains unknown, current hypotheses
focus on the roles played by activating
cytokines. VAHS has been reported in
connection with a variety of viruses:
adenovirus, cytomegalovirus, dengue,
Epstein-Barr, hepatitis A, hepatitis B,
hepatitis C, herpes simplex, HIV,
human herpesvirus 6, human her-
pesvirus 8, influenza A (antigenic type
H1N1), measles, parainfluenza type
III, parvovirus B 19, rubella, and vari-
cella-zoster (2). This report is the first
of a VAHS case associated with a
mumps virus infection. The clinical
course of VAHS is highly variable,
and in some cases, especially in
Epstein-Barr virus infection, VAHS is
a dramatic illness with a potentially
fatal outcome (2). This case implies
that mumps VAHS may have a posi-
tive prognosis.
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Imported Cutaneous
Diphtheria,
Germany, 1997–2003
To the Editor: The March 2004
report by de Benoist et al. on the inci-
dence of imported cutaneous diphthe-
ria in the United Kingdom (1)
prompted us to describe the situation
of cutaneous diphtheria in Germany
and to analyze the cases reported to
the German Consiliary Laboratory on
Diphtheria since its establishment at
our institute in 1997. The laboratory
provides advisory and diagnostic
services mainly to microbiologic lab-
oratories throughout Germany. 
From 1997 to 2003, 6 cases of
cutaneous infections caused by toxi-
genic Corynebacterium diphtheriae
were documented (Table). None of
these was accompanied by secondary
diphtheria infection. Toxigenicity
was determined by both dtx poly-
merase chain reaction and Elek test
(2). As in the United Kingdom, all
cases for which clinical information
was available (N = 5) were imported.
Three were found in tourists who had
traveled to tropical countries: a
20-year-old diver had injured her heel
after stepping on coral in Thailand; a
60-year-old tourist had a chronic
ulcer develop in the thigh after a trip
to Indonesia (no history of an insect
bite); and a 39-year-old traveler to
Kenya returned with a purulent ear
infection with no memory of trauma
or insect bite. The remaining import-
ed C. diphtheriae skin infections
were reported in 2 Angolan children,
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5 and 10 years of age, who were
brought to Germany by a humanitari-
an organization for surgery on severe
gun wounds to their lower extremities
(foot and thigh with chronic
osteomyelitis, respectively). To our
knowledge, these reports are the first
of cutaneous diphtheria in gunshot
wounds in recent years. Moreover, in
the patient with the thigh wound, C.
diphtheriae was also isolated from a
deep fistula, which suggests involve-
ment of C. diphtheriae in the chronic
osteomyelitis. 
As in the United Kingdom, all
cases of diphtheria reported since 1997
were caused by C. diphtheriae mitis. In
4 of 5 cutaneous diphtheria patients
who had an available medical history,
mixed infections with Staphylococcus
aureus and Streptococcus pyogenes
were found; 3 of 5 patients were not
sufficiently vaccinated against diph-
theria as recommended. Systemic
symptoms, such as malaise and gener-
al weakness, developed in the 20-year-
old Thailand tourist, although she had
received a booster dose just before her
travel. Cutaneous diphtheria must be
expected even in vaccinated patients;
for instance, among serum samples of
287 healthy German adults with a
complete record of basic immuniza-
tion against diphtheria, only 42.2%
showed full serologic protection
as indicated by antitoxin levels
> 0.1 IU/mL (3).
As de Benoist et al. outline, cuta-
neous diphtheria might be difficult to
diagnose because of its unspecific
clinical appearance and the presence
of mixed infections in chronic
nonhealing skin lesions. Because of
the nearly complete disappearance of
cutaneous diphtheria in many parts of
the western world, microbiologists
lack experience in identifying C. diph-
theriae grown from specimens. From
1997 to 2003, approximately one fifth
of the strains sent to our Consiliary
Laboratory on Diphtheria for species
identification and toxin testing were
either nondiphtheria Corynebacterium
spp. or noncoryneform bacteria of dif-
ferent genera (including lactobacilli,
Dermabacter hominis, and
Propionibacterium acnes).
Clinicians (4) and microbiologists
(5) should be aware of the possibility
of cutaneous diphtheria in chronically
infected skin lesions in patients
returning from disease-endemic
regions. Medical personnel should
include this in civilian as well as mil-
itary health services, since our cases
indicate that toxigenic C. diphtheriae
might affect not only travel-related
skin injuries caused by leisure or
tourist activities but also wounds in
patients from war regions in diphthe-
ria-endemic areas.
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Antimicrobial Drug
Consumption in
Companion Animals 
To the Editor: During the last
decade, use of antimicrobial drugs for
growth promotion and therapeutic
treatment in food animals has received
much attention. The reservoir of resist-
ant bacteria in food animals implies a
potential risk for transfer of resistant
bacteria, or resistance genes, from
food animals to humans. Subsequent
emergence of infections in humans,
caused by resistant bacteria originat-
ing from the animal reservoir, is of
great concern. These unintended con-
sequences of antimicrobial drug use in
animals led to termination of antimi-
crobial growth promoters in food ani-
mals in countries in the European
Union, including Denmark, where the
consumption of antimicrobial drugs
by production animals was reduced by
50% from 1994 to 2003 (1).
In Denmark, the VetStat program
monitors all veterinary use of medi-
cines for animals. VetStat is based on
reporting from the pharmacies and
from veterinary practitioners and con-
tains detailed information, such as
animal species, reason for prescrip-
tion, and dosage on each prescription.
In Denmark, antimicrobial drugs can
be obtained only by prescription and
only at pharmacies. 
So far, use of antimicrobial drugs
in companion animals has received
little attention; monitoring programs
have focused on antimicrobial drug
consumption in food animals.
According to data generated by the
VetStat program in 2003, consump-
tion of fluoroquinolones and
cephalosporins in companion animals
was substantial when compared to
consumption in food animals (1).
Fluoroquinolones and cephalosporins
are antimicrobial drugs ranked by the
U.S. Food and Drug Administration
as critically important in human med-
icine, and for which emergence of
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